These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25514384)

  • 1. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
    Kim MK; Park HS; Cho JH; Kim GS; Won C
    Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D3 receptor-modulated neuroprotective effects of lisuride.
    Kim M; Lee S; Cho J; Kim G; Won C
    Neuropharmacology; 2017 May; 117():14-20. PubMed ID: 28131770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration.
    Guevara-Salinas A; Netzahualcoyotzi C; Álvarez-Luquín DD; Pérez-Figueroa E; Sevilla-Reyes EE; Castellanos-Barba C; Vega-Ángeles VT; Terán-Dávila E; Estudillo E; Velasco I; Adalid-Peralta L
    CNS Neurosci Ther; 2024 Aug; 30(8):e14883. PubMed ID: 39097919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
    Le WD; Jankovic J; Xie W; Appel SH
    J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
    Vu TQ; Ling ZD; Ma SY; Robie HC; Tong CW; Chen EY; Lipton JW; Carvey PM
    J Neural Transm (Vienna); 2000; 107(2):159-76. PubMed ID: 10847557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
    Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway.
    Chu JM; Chen LW; Chan YS; Yung KK
    Neuropharmacology; 2011 Dec; 61(8):1389-98. PubMed ID: 21907219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three paradoxes related to the mode of action of pramipexole: The path from D2/D3 dopamine receptor stimulation to modification of dopamine-modulated functions.
    Szabadi E
    J Psychopharmacol; 2024 Jul; 38(7):581-596. PubMed ID: 39041250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
    Zengin-Toktas Y; Authier N; Denizot H; Chassain C; Hafidi A; Llorca PM; Durif F
    Neuropharmacology; 2013 Jul; 70():74-82. PubMed ID: 23347953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.
    Voshavar C; Shah M; Xu L; Dutta AK
    Neurotox Res; 2015 Nov; 28(4):302-18. PubMed ID: 26201265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
    Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
    Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.